Q-omics provides the consensus-scored ASH2L profile across patient tissues and cancer cell-line models. ASH2L expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ASH2L is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, ASH2L protein abundance shows 26,645 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, THCA, and GBM as cancer lineages where ASH2L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ASH2L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ASH2L survival associations across molecular data types. ASH2L RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ASH2L RNA expression–survival associations across cancer types. High ASH2L expression shows unfavorable associations in ACC, KICH and STAD, but favorable associations in KIRC, HNSC and LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ASH2L RNA expression.
This table summarizes ASH2L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ASH2L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ASH2L shows lower tumor expression in THCA and KICH and higher tumor expression in LUSC, STAD, BRCA and CHOL. The THCA box plot shows higher ASH2L RNA expression in normal versus tumor tissue (log2 FC = −0.215, t-test p = .002).
This table shows molecular features associated with ASH2L in patient tissues and cancer cell lines. In patient samples, ASH2L shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ASH2L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
